<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00929812</url>
  </required_header>
  <id_info>
    <org_study_id>GluGhr-study 01082005</org_study_id>
    <secondary_id>EudoraCT 2005-003714-15</secondary_id>
    <secondary_id>Prüfplancode 01082005</secondary_id>
    <secondary_id>BfArM 61-3910-4031020</secondary_id>
    <secondary_id>EK EA4/108/05</secondary_id>
    <nct_id>NCT00929812</nct_id>
  </id_info>
  <brief_title>Glucagon Modulation of Ghrelin Secretion</brief_title>
  <official_title>The Mechanisms Underlying the Glucagon-Induced Suppression of Ghrelin Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining
      glucose homeostasis in vivo. It is well known that intramuscular glucagon administration
      stimulates growth hormone (GH), adrenocorticotropic hormone (ACTH) and cortisol release in
      humans. Recently, it has been shown that glucagon induces a remarkable decrease in ghrelin
      levels. The mechanisms underlying this effect are unclear and the role of changes in glucose,
      insulin, glucagon-like peptide-1 (GLP-1) and catecholamines are widely discussed. The aim of
      the present study is to further evaluate the effect of glucagon on ghrelin secretion and the
      possible role of the above mentioned factors in mediating this effect.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2006</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in satiety scale, total and acylated ghrelin concentrations.</measure>
    <time_frame>During 240 min after Glucagon/Placebo administration.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose, insulin and NEFA concentrations.</measure>
    <time_frame>During 240 min after Glucagon/Placebo administration.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Obesity</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Glucagon hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GlucaGen® 1 mg/1 ml intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 ml NaCl 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon hydrochloride (GlucaGen®)</intervention_name>
    <description>1 mg/1 ml of glucagon hydrochloride intramuscularly</description>
    <arm_group_label>Glucagon hydrochloride</arm_group_label>
    <other_name>GlucaGen® (Novo Nordisk Pharma, MA:28288.00.00)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <description>1 ml NaCl 0.9% intramuscularly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects &gt; 18 and &lt; 60 years old.

          -  Patients with diabetes type 1 should fulfill the following criteria:

               -  ICT Insulin therapy was necessary within the first 3 months after diagnosis;

               -  HbA1c-Wert &lt; 7%.

        Exclusion Criteria:

          -  Diabetes type 1 or 2 (for the healthy group).

          -  Biochemical evidence of impaired hepatic or renal function.

          -  History of cardiovascular disease.

          -  Uncontrolled hypertension.

          -  Current inflammatory, malignant or psychiatric disease.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayman M Arafat, Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite Campus Benjamin Franklin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Arafat AM, Perschel FH, Otto B, Weickert MO, Rochlitz H, Schöfl C, Spranger J, Möhlig M, Pfeiffer AF. Glucagon suppression of ghrelin secretion is exerted at hypothalamus-pituitary level. J Clin Endocrinol Metab. 2006 Sep;91(9):3528-33. Epub 2006 Jun 20.</citation>
    <PMID>16787987</PMID>
  </reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <last_update_submitted>June 29, 2009</last_update_submitted>
  <last_update_submitted_qc>June 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ayman M Arafat, Dr.med.</name_title>
    <organization>Charite Campus Benjamin Franklin</organization>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>food intake</keyword>
  <keyword>glucagon</keyword>
  <keyword>ghrelin</keyword>
  <keyword>glucose</keyword>
  <keyword>insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

